申请人:Dong Wha Pharm. Ind. Co., Ltd.
公开号:US05929103A1
公开(公告)日:1999-07-27
The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which ----, R.sub.1, and R.sub.2 are as defined in the specification.
本发明涉及一种新颖的芳基磺酰基咪唑酮衍生物,其化学式如下(I),与已知的磺酰脲类抗肿瘤药物相比,具有卓越的抗肿瘤活性以及较小的副作用: ##STR1## 其药学上可接受的盐和立体异构体,其中----,R.sub.1和R.sub.2如规范中所定义。